RxDoctor Payments Data

Ashesh Modi, MD

Gastroenterology · Newark, DENPI 1174674816

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 25.7% of the total. That places this record below the midpoint for gastroenterology clinicians in DE, where the typical reported total is $2,631.

$2,631in general payments, 2019–2025

Across 125 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$676
  • Madrigal Pharmaceuticals$185
  • Pfizer$184
  • Johnson & Johnson$172
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$163
  • Bristol Myers Squibb$143
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,631100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,631 in reported general payments places this provider in the 50th percentile of 50 gastroenterology providers in Delaware.

See all gastroenterology providers in Delaware

Medicare billing

Part B allowed, 2024
$327,276
Medicare patients
583
Services billed
10,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide14$20,540
Mesalamine22$13,160
Balsalazide Disodium25$3,997
Omeprazole126$2,576
Sucralfate12$1,656
Pantoprazole Sodium75$1,444
Lubiprostone11$945
Dicyclomine Hcl34$790
Ondansetron Hcl27$718
Esomeprazole Magnesium11$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$676$20,54014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 50 gastroenterology providers in Delaware.

Other gastroenterology in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →